November 3, 2016—A new federal rule that changes how Medicare pays for services at certain hospital off-campus departments likely won't prevent hospitals from enrolling the sites in the 340B drug discount program in 2017. On Nov. 1, the Centers for Medicare and Medicaid Services published a final rule implementing the site neutrality provision in Section 603 of the … [Read more...]
Delaware Drops Medicaid 340B Carve-Out Requirement
November 2, 2016—Delaware Medicaid has dropped what was thought to be a first-of-its-kind state requirement that would have barred healthcare providers from using 340B-purchased drugs for Medicaid beneficiaries. … [Read more...]
340B Hospitals Ask DOJ for EpiPen Overcharge Investigation
November 1, 2016—Hospitals and health systems in the 340B drug discount program have asked the U.S. Justice Department to investigate whether drugmaker Mylan overcharged 340B healthcare providers for EpiPen anaphylaxis rescue auto-injectors. … [Read more...]
340B Is Good For Americans. Why Is Big Pharma Trying to Gut it?
November 1, 2016—Thanks to the money its saves from being in the 340B drug discount program, a Virginia hospital could afford to perform heart surgery on an unemployed, uninsured man, put him on a blood thinner, and then keep close tabs on his health post-discharge – all for free. A Boston 340B hospital likewise can afford to keep first responders supplied with opioid overdose … [Read more...]
Specialty Drug Claims Costs Expected to Rise Almost 20 Percent
October 27, 2016—Healthcare payers expect claims costs for specialty and biotech drugs to rise by almost 20 percent next year, a leading health benefits consulting firm says. … [Read more...]
Investors Press Drug Companies About Unjustified Price Increases
October 25, 2016—Socially responsible investors want 17 leading U.S. and foreign drug companies to provide "more comprehensive disclosure about the rationale for price increases." … [Read more...]
OMB Reviewing 340B Final Rule Creating Fines for Overcharges
October 24, 2016—The Department of Health and Human Services' final 340B program rule setting standards for calculating ceiling prices and implementing civil monetary penalties for drugmakers that “knowingly” and “intentionally” overcharge covered entities for covered outpatient drugs is a step closer to release. … [Read more...]